Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS).
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience / Rovesti, Giulia; Orsi, Giulia; Kalliopi, Andrikou; Vivaldi, Caterina; Marisi, Giorgia; Faloppi, Luca; Foschi, Francesco Giuseppe; Silvestris, Nicola; Pecora, Irene; Aprile, Giuseppe; Molinaro, Eleonora; Riggi, Laura; Ulivi, Paola; Canale, Matteo; Cucchetti, Alessandro; Tamburini, Emiliano; Ercolani, Giorgio; Fornaro, Lorenzo; Andreone, Pietro; Zavattari, Patrizia; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: GASTROINTESTINAL TUMORS. - ISSN 2296-3774. - 6:3-4(2019), pp. 92-107-107. [10.1159/000502714]
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience
Rovesti, Giulia;Andreone, Pietro;Casadei-Gardini, Andrea
2019
Abstract
Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS).
| File | Dimensione | Formato | |
|---|---|---|---|
|
502714.pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
805.11 kB
Formato
Adobe PDF
|
805.11 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
